# Vorozole

| | |
|---|---|
| **Cat. No.:** | HY-19599 |
| **CAS No.:** | 129731-10-8 |
| **Molecular Formula:** | $C_{16}H_{13}ClN_6$ |
| **Molecular Weight:** | 324.77 |
| **Target:** | Cytochrome P450 |
| **Pathway:** | Metabolic Enzyme/Protease |
| **Storage:** | -20°C, stored under nitrogen<br>* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | Vorozole is a potent and selective, orally active non-steroidal aromatase inhibitor[1][2]. Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer[3]. |
| **$IC_{50}$ & Target** | Aromatase |
| **In Vitro** | Vorozole inhibits aromatase activity with an $IC_{50}$s of 1.4 nM in FSH-stimulated rat granulosa cells[4].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| **In Vivo** | Vorozole (0.8-1.25 mg/kg; Gavage; daily for 77 dayss) shows antitumor effect and increase the release of serum insulin-like growth factor (IGF)-1 and serum testosterone levels[3].<br>Vorozole (p.o.; 5 days) dose-dependently reduced uterus weight and completely inhibited tumor aromatase in ovariectomized nude mice[4].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

| | |
|---|---|
| Animal Model: | Female Sprague-Dawley rats[3] |
| Dosage: | 0.08, 0.16, 0.31, 0.63 or 1.25 mg/kg |
| Administration: | Gavage; daily (starting at 43 days of age) for 77 days; given a single i.v. dose of methylnitrosourea (MNU) (50 mg/kg body wt) after 7 days |
| Result: | Caused a dose-dependent increase in body weight gain and decrease in cancer incidence, increased the insulin-like growth factor (IGF)-1, serum testosterone levels. |

## REFERENCES

[1]. Wouters W, et al. Pharmacology of vorozole. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):617-21.

[2]. Wiseman LR, et al. Vorozole. Drugs Aging. 1997 Sep;11(3):245-50; discussion 251-2.

[3]. Lubet RA,et al. Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis. 1998 Aug;19(8):1345-51.

[4]. Wouters W, et al. Pharmacology of vorozole. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):617-21.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA